Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance

Biogen (BIIB) PT Raised to $285 at UBS Following Strong 2Q

July 26, 2017 8:44 AM EDT

UBS raised its price target on Biogen (NASDAQ: BIIB) to $285.00 (from $270.00) while maintaining a Neutral rating following the company's 2Q. BIIB recorded a $284M top-line beat. EPS also came in ahead with a $0.53 beat.

Despite a strong 2Q print, the mid-to-long term outlook... More

Biogen (BIIB) PT Raised to $319 at Deutsche Bank

July 26, 2017 6:24 AM EDT

Deutsche Bank raised its price target on Biogen (NASDAQ: BIIB) to $319.00 (from $315.00) while maintaining a Buy rating amid solid Q2 results and strategic review.

Analyst Andrew Peters commented, "The outperformance, driven primarily by strength in the MS franchise, as well as by continued... More

Biogen (BIIB) Tops Q2 EPS by 59c, Sales Beat; Raises Outlook

July 25, 2017 6:31 AM EDT

Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.04, $0.59 better than the analyst estimate of $4.45. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $2.81 billion.

Total revenues of $3.1 billion, a 6% increase versus the prior year and a 15% increase excluding hemophilia revenues*.Revenue growth was driven by strength in MS revenues, which increased 5% versus prior year. This included a 13% increase in... More